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1  |  INTRODUC TION
Peanut allergy (PA) is one of the most common food allergies among 
children in Western nations1 and is often a lifelong condition.2 
Onset of PA typically occurs in early childhood3–6 and is associated 
with more severe reactions than other food allergies.7 In contrast 
to food allergies such as milk, egg, wheat and soy that resolve in 
childhood or adolescence in approximately half to the majority of 
cases,8,9 PA persists into adulthood in approximately 75%–80% of 
children.2,10
Until recently, the recommended management strategy for PA 
was limited to the combination of strict allergen avoidance along 
with an action plan, including having an adrenaline auto-injector 
(AAI) on hand in case of accidental exposure and reaction to pea-
nut,11,12 which is sometimes referred to as an avoidance manage-
ment strategy.13 However, the 2018 European Academy of Allergy 
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Peanut allergy (PA) currently affects approximately 2% of the general population 
of Western nations and may be increasing in prevalence. Patients with PA and their 
families/caregivers bear a considerable burden of self-management to avoid acciden-
tal peanut exposure and to administer emergency medication (adrenaline) if needed. 
Compared with other food allergies, PA is associated with higher rates of accidental 
exposure, severe reactions and potentially fatal anaphylaxis. Approximately 7%–14% 
of patients with PA experience accidental peanut exposure annually, and one-third to 
one-half may experience anaphylaxis, although fatalities are rare. These risks impose 
considerably high healthcare utilization and economic costs for patients with PA and 
restrictions on daily activities. Measures to accommodate patients with PA are often 
inadequate, with inconsistent standards for food labelling and inadequate safety poli-
cies in public establishments such as restaurants and schools. Children with PA are 
often bullied, resulting in sadness, humiliation and anxiety. These factors cumulatively 
contribute to significantly reduced health-related quality of life for patients with PA 
and families/caregivers. Such factors also provide essential context for risk/benefit 
assessments of new PA therapies. This narrative review comprehensively assessed 
the various factors comprising the burden of PA.
K E Y W O R D S
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and Clinical Immunology (EAACI) Guidelines for management of 
food allergy recommended oral immunotherapy (OIT) as a treat-
ment option to increase the reaction threshold in children with PA 
from around 4–5 years of age (strength/evidence level/grade of rec-
ommendation: strong/1/A) (Table S1).14 EAACI guidelines further 
stated that post-discontinuation effectiveness of OIT is suggested, 
but not yet confirmed.
The combined factors of the risk of potentially life-threatening 
and often traumatic accidental allergic reactions, lifelong persistence 
of PA in the majority of individuals, responsibility for self-man-
agement of risks and the lack of any approved treatments for this 
condition, all contribute to a significant burden of illness associated 
with PA.15,16 Multiple studies have investigated specific aspects of 
the burden of PA, such as impact on health-related quality of life 
(HRQoL),17–19 risks of accidental exposures to peanut20 and costs 
of self-management of PA.21 However, comprehensive reviews that 
assess these various factors together to provide an updated and ho-
listic perspective on the burden of PA are lacking. Such perspectives 
are particularly needed in light of recent evidence that PA incidence 
and prevalence may be increasing,8,22 thus potentially adding to the 
societal burden of PA.
These perspectives are particularly relevant due to recent ad-
vances in PA management, which pose new choices and important 
questions for clinicians, patients with PA and their caregivers. Recent 
clinical trials have demonstrated the benefit of introducing peanut 
to children at a young age to reduce the risk of developing PA,23 
prompting the publication of US, British and Australasian guidelines 
for early introduction of peanut to infants/at-risk infants.24–26 In 
addition, the novel oral immunotherapy Peanut (Arachis hypogaea) 
Allergen Powder-dnfp, formerly known as AR101, was recently ap-
proved to mitigate allergic reactions that may occur with accidental 
exposure to peanuts in individuals 4–17 years of age with a con-
firmed diagnosis of PA.27,28 Other immunotherapies are in phase 2 
and 3 development.29–31 A complete and accurate assessment of the 
current burden of self-managed PA is needed to allow for full con-
sideration of the role of emerging and future management options.
1.1  |  Objective
This article will review in comprehensive narrative format the impact 
of the risks of PA and the burden of self-management on peanut-
allergic children, adolescents and their families.
1.2  |  Methods
1.2.1  |  Narrative review vs systematic review
This narrative review was designed to assess the latest data concern-
ing the burden of PA from a broad and multifaceted perspective, in-
cluding impacts in socioeconomic, clinical, psychosocial and HRQoL 
domains. Because narrative reviews are generally comprehensive and 
cover a wider range of issues within a given topic, as compared to the 
narrow focus and prescribed methods of a systematic review, the use 
of a systematic or meta-analysis review method was deemed imprac-
tical for the purpose of assessing the spectrum of factors associated 
with PA burden. Additionally, since multiple individual searches were 
required for each topic, using consistent, precise selection/elimina-
tion criteria across topics would have inherently resulted in the omis-
sion of several publications that were critical to our report.
We searched the United States National Institute for Biotechnology 
Information/National Institutes of Health/National Library of 
Medicine PubMed database (https://www.ncbi.nlm.nih.gov/pubmed) 
for studies pertaining to the burden of PA in the following main key-
word/topic areas: peanut allergy prevalence and incidence, accidental 
exposures, anaphylaxis and severe reactions, healthcare utilization, 
economic costs, mortality, comorbidities, burden of peanut allergy on 
the individual and family (including requirements of disease self-man-
agement) and peanut allergy impact on HRQoL. The searches for 
each topic area, search terms used for each, and main results of each 
search are illustrated in Figure S1. Initial searches were limited to data 
published within the past 2 years. If these data were insufficient, we 
conducted a second search within a 10-year time frame. We also in-
corporated articles as appropriate if publications retrieved during our 
searches pointed to essential prior studies.
2  |  RESULTS
2.1  |  Peanut allergy prevalence and incidence
Estimates of PA prevalence have varied in part due to the differ-
ent methods utilized for determining its presence, ranging from 
self-report to skin prick test (SPT), peanut-specific immunoglobulin 
E (psIgE) testing and oral food challenge (OFC), as well as different 
thresholds for each test, and the age cohorts and regional popula-
tions studied. Some evidence also suggests incidence and preva-
lence of PA may be increasing, thus introducing a further challenge 
to accurate assessment.8,32 Studies reporting prevalence of PA pub-
lished since 2010 are listed in Table 1.
Overall, studies have generally reported PA prevalence rates 
between 1% and 2% in Western nations (Table 1). Incidence and 
prevalence of PA appear to be less common in Asia and other 
global areas, although epidemiological studies of PA in non-West-
ern regions have been sparse (Table 1).22 One cross-sectional, 
multicentre study reported a PA prevalence of 0.8% in South 
African children based on SPT and OFC,33 and a cross-sectional 
study in Kuwaiti schoolchildren aged 11–14 years reported a PA 
prevalence of 1.3% based on clinical history.34 A retrospective, 
single-centre cohort study found that among 98 Singaporean chil-
dren presenting with anaphylaxis, peanut was the most common 
trigger of anaphylactic events, although no cases of peanut-trig-
gered anaphylaxis were documented in a similar study conducted 
15 years earlier, possibly indicating effects of changes in dietary 
habits.35,36 In both studies, anaphylaxis cases were indicated by 
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hospital and emergency room discharge codes and confirmed by 
presence of clinical symptoms; however, the later study used the 
2008 Sampson criteria for diagnosis, while these criteria were not 
available for the earlier study.35,36
Some, but not all, data also indicate that PA incidence and prev-
alence may be increasing in Western nations.3,37,38 A longitudinal 
national US claims database study found that annual incidence of 
PA in 1-year-old children had increased from 1.7% in 2001 to 5.2% 
in 201739. A recent study in a representative US population of over 
40,000 individuals found that PA impacts 2.2% of children and 1.8% 
of adults.40, 41 In addition, a retrospective cohort study of children 
aged 0–6 years in the Australian Capital Territory reported increas-
ing incidences of PA (children born in 2001, 0.73%; children born in 
2004, 1.15%).42
Among prevalence studies, a nationwide US study found a 3-fold 
increase in self-reported PA prevalence in children between 1997 
(0.4%) and 2008 (1.4%),37 although actual prevalence figures may 
be inflated in studies only considering self-reported PA.8,43 A na-
tionwide English study of clinician-recorded PA diagnosis found 
that while incidence remained stable, the prevalence of PA dou-
bled, from 2001 (0.24 per 1000 patients) to 2005 (0.51 per 1000 
patients).38 More recently, a three-decade, retrospective UK medi-
cal records database study found that point prevalence per 100,000 
had risen from 31 to 202 in the total population, and from 116 to 
635 in children from 2000 to 2015.44 In addition, this study found 
that incidence of PA overall in the UK had more than doubled, from 
8.6 to 18.2 per 100, 000, between 2000 and 2015. However, sta-
ble PA prevalence has been reported in two Canadian studies for 
the periods of 2000 to 2007 in Montreal45 and 2010 to 2017 across 
Canada46 and in a study conducted on the Isle of Wight, UK between 
the late 1990s and 2004.47
3  |  HE ALTHC ARE BURDEN
3.1  |  Risks of accidental exposure, severe reactions 
and anaphylaxis
Even with adherence to standard self-management behaviours,14,16 
risk of accidental exposure to peanut is still high among individuals 
with PA. The widespread use of peanuts in various foods makes it 
particularly difficult to avoid peanut exposure in the home, where 
children play or at school.7 Data on the rate of accidental reactions in 
patients with PA have varied, likely due to variations in study design, 
geographic region and decade of study (Table 2).6,20,41,48–53
Data on the frequency of anaphylaxis in patients with PA are 
limited, in part because of varying definitions of anaphylaxis used. 
Multiple studies in Western nations have reported that severe al-
lergic reactions due to peanut occur more frequently than to other 
food allergies.40,54 A nationwide US study on food allergies in chil-
dren (n = 38,408) found that a history of severe reactions was more 
common in children with PA (59.2%) vs all other food allergies (42.3% 
rate of severe reactions overall).40 Similarly, a nationwide 2009–2010 
US survey study in 38,480 children found that a significantly higher 
percentage of children with PA (n = 754) had experienced a severe 
reaction to peanut vs children with food allergy in general (n = 2464) 
(53.7% vs 41.0%; p < .001).7 Among US adults with PA, 68% report 
at least one severe peanut-allergic reaction vs a 51% overall rate of 
any severe food-allergic reactions among all US adults with food al-
lergy.41 The Australian SchoolNuts Study, which included 547 ad-
olescents aged 10–14 years with possible food allergy, found that 
38.6% of all confirmed anaphylaxis episodes and 30.6% of uncon-
firmed anaphylaxis episodes were reactions to peanut, the highest 
percentages of any food causes.55
Studies in the US and Canada have reported that 11%–17% of 
accidental exposures were severe (Table 2).20,50,51 A cross-sec-
tional nationwide US study in 754 children with PA reported an 
anaphylaxis rate of 14.2%, compared with 8.1% in children with 
other food allergies,7 and a UK clinical practice database study 
found a considerably lower anaphylaxis rate of 1.2% of all patients 
(children and adults) with PA vs 0.007% of matched controls.44 
Another US study reported that anaphylaxis occurred in approx-
imately 35% of 525 children over a 5-year period,6 and a smaller 
study (n = 83) reported a 5-year rate of reactions with ‘poten-
tially life-threatening symptoms’ in approximately 52% of children 
(Table 2).53 Accidental exposures causing anaphylaxis frequently 
occur in children whose initial reactions leading to diagnosis were 
mild (Figure 1),6,53 demonstrating the unpredictable nature of PA 
reaction severity.56 While varying methodologies of reporting re-
actions and varying definitions of anaphylaxis make it difficult to 
put a finite number on the frequency of anaphylaxis to peanut, it 
is evident that severe and accidental reactions are common in pa-
tients with PA. Several studies also relied on self-report, which is 
prone to recall bias and misclassification. More studies are needed 
that examine current, consistent and well-validated criteria for the 
diagnosis of anaphylaxis.
3.2  |  Healthcare utilization
In the European Anaphylaxis Registry, peanut is the most common 
trigger involved in anaphylaxis cases in both children and adoles-
cents, accounting for 26.3% and 18.3% of food-related anaphylaxis 
cases, respectively.54 Peanut is also the most common food trig-
ger involved in most studies of paediatric emergency department 
(ED) admissions overall and in paediatric intensive care unit (ICU) 
admissions in North America; peanut is the second most common 
trigger, after milk, in France.57,58 Anaphylaxis to peanut is also as-
sociated with high rates of hospital admission following ED visits, 
compared with other food-related and non-food-related causes of 
anaphylaxis.59 Recent US survey data show that 23% of children40 
and 20% of adults41 with PA reported an ED visit in the past year 
due to a food-allergic reaction. A healthcare utilization study in the 
UK demonstrated that compared to matched control groups (normal 
and with/without an atopic condition) patients with PA had a greater 
number of contacts (per person-year) with primary care providers, 
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inpatient care, prescriptions, outpatient care, and accident and 
emergency admissions.60
An epidemiological study in the US, Canada and Mexico of paedi-
atric anaphylaxis ICU admissions between 2010 and 2015 (n = 1989) 
found that peanut was the most frequent trigger, accounting for 
39% of such cases (Figure 2).57 In addition, a study of paediatric 
ED visits and hospital admissions due to food-induced anaphylaxis 
in Illinois between 2008 and 2012 found that such cases had in-
creased significantly over the period (p < .005), with a 30% average 
annual increase observed for peanut-induced events (Figure 3).61 A 
nationwide Italian study found that the rate of hospital admissions 
for food-induced anaphylaxis in children had increased from 0.001% 
in 2001 to 0.005% in 2011 (p < .05) and that while peanut exposure 
was a less frequent cause than milk and eggs, it was the cause of 1 
out of every 4 deaths that occurred in patients aged >14 years.62
Although sparse, these utilization data support and confirm the 
studies discussed in the previous section showing relatively high 
rates of anaphylaxis and severe reactions despite their diversity of 
methodology.
3.3  |  Economic burden
The economic burden of PA includes both direct and indirect costs, 
each of which have been investigated in several studies.
3.3.1  |  Direct medical costs
Among US studies, a retrospective national US government healthcare 
database analysis of the annual direct costs of food allergy, including 
PA, over the years 2006 and 2007 estimated that total annual medical 
costs were $225 million (2007 US dollars), with office visits account-
ing for just over half of the cost; the rest of the cost was split among 
ED visits, inpatient and outpatient visits, ambulance transfers, and 
AAIs.63 A survey of US caregivers of children with food allergy esti-
mated direct medical costs of $4.3 billion annually (or $724 per child).64 
The caregivers also reported a willingness to pay $3504 per year per 
child for a safe and effective treatment that would allow the child to 
eat all foods; that total cost was estimated at $20.8 billion annually, a 
number similar to the total estimated indirect costs spent on children 
with food allergy ($20.5 billion). The total annual economic burden of 
food allergy was estimated to be $24.8 billion, which combined direct 
($4.3 billion) and indirect costs.64 A 2013 pan-European, case-control 
F I G U R E  1  History and nature of 
reactions to peanut from a single-centre 
study in 83 children with peanut allergy 
followed for 5 years. Approximately 
one-third of subjects who had non–life-
threatening first reactions (19 of 61; 
31.1%), and more than half of those who 
had life-threatening first reactions (12 of 
22; 54.5%), subsequently experienced 
a/another potentially life-threatening 
reaction. All reactions subsequent to first 
reaction were from accidental exposure 
(as opposed to reactions occurring during 
food challenges). Reproduced with 
permission from Vander Leek et al53
F I G U R E  2  A study of all anaphylaxis admissions to North 
American (United States, Canada and Mexico) paediatric intensive 
care units between 2010 and 2015 (N = 1989) found that peanut 
was the most common trigger. FA, food allergy; Hx, history. 
Reproduced with permission from Ramsey et al57
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survey study conducted among participants in the EuroPrevall study 
(n = 1411) found that the mean costs of health care over the previ-
ous year for adults and children with possible food allergy (symptoms 
unconfirmed by psIgE testing) were I$2016 and I$2197 vs I$1089 and 
I$863 for controls, respectively.65
Among studies that assessed the costs of PA specifically, a 2017 
white paper found that patients with PA averaged approximately 1.25 
medical services per patient in 2016 based on an analysis of nation-
wide US medical insurance claims.66 On average, patients with PA were 
charged $236.73 per patient for services over the 2016 year, with insur-
ance covering $100.11. A US study assessed value-based pricing for an 
AAI, which is substantially higher in the US than most other countries, 
for community-based anaphylaxis management in patients with PA.21 
This study found that given the average pharmacy AAI cost of $715 in 
2016, combined with 2018 reported costs for ED visits and hospitaliza-
tions for anaphylaxis symptoms, the cost of anaphylaxis preparedness 
and treatment in those prescribed an AAI over an 80-year time horizon 
was $25,478 (95% CI: $25,399-$25,447) vs $654 (95% CI: $685-$743) 
for those not prescribed an AAI. Assuming that AAI prescription reduced 
anaphylaxis fatality risk by 10- to 100-fold, the estimated cost-effective 
price range for AAI was $24–$264, indicating that AAI at its then-current 
US price was not cost-effective. A retrospective cohort study of PA costs 
among patients with PA in the UK (n = 15,483), reported per-person an-
nual incremental healthcare costs vs healthy controls of £333, ranging 
up to £392 for those prescribed an AAI, and £662 per year for those with 
history of anaphylaxis; total excess costs of PA in the UK were between 
£33 and £44 million in 2015.60 The average cost of an AAI in the UK 
in 2017 was £25.80 (approximately US$32.10).67 Comparable studies of 
PA costs in regions/countries other than the US and UK are lacking. The 
available studies rely on modelling and reflect vastly disparate healthcare 
costs in different countries; thus, defining the exact costs of PA across 
countries remains difficult. However, the consistent finding among these 
studies is that PA raises healthcare costs.
3.3.2  |  Indirect medical costs
A Swedish case-control study demonstrated that indirect costs of 
food allergy were significantly higher in families with food-allergic 
children (excluding adolescents) compared with controls.68 The US 
retrospective, government healthcare database study mentioned 
above also estimated annual indirect costs (eg lost work productivity 
and earnings) of food allergy including PA for 2006–2007 to be $115 
million (2007 US dollars).63 A cross-sectional US survey study64 es-
timated annual lost labour productivity due to food allergy at $773 
million, or $130 per child, associated with accompanying child to 
medical visits; $5.5 billion, or $931 per child, in annual out-of-pocket 
costs, including special diets/allergen-free foods, changes in child-
care, and changes in schools; and annual opportunity costs due to 
forgone labour market activities, at $14 billion, or $2399 per child. 
While these studies have limitations, similar to those analysing direct 
costs, an overall trend towards increased indirect costs is apparent.
3.4  |  Mortality
While rates of fatal anaphylaxis due to peanut are low, peanut is 
among the most frequent food allergens implicated in fatal ana-
phylaxis. This finding has been documented in the US,69–71 the 
UK,72,73 Australia74 and France.75 A 2013 meta-analysis of data on 
fatal food-related anaphylaxis found that the incidence of peanut-
induced mortalities was 2.13 per million person-years (95% CI: 
1.09–4.16; I2 = 86.4%; p < .001), which was higher than the rate for 
all food allergies (1.81 per million person-years [95% CI: 0.94–3.45; 
I2 = 94.8%; p < .001]).76 UK data showed that deaths from food-re-
lated anaphylaxis usually occurred in allergic people whose previous 
reactions had been mild, underlining the unpredictability of reaction 
F I G U R E  3  From an Illinois (United States) state hospital 
association database study of emergency department (ED) visits or 
hospitalizations for food-induced anaphylaxis in Illinois hospitals 
from 2008 to 2012 (n = 1893; 10.9 ED visits or hospitalizations per 
100,000 children). A. Rates of ED visits and hospital admissions due 
to food-induced anaphylaxis by food allergen trigger. B. Annual per 
cent increase in ED visits from 2008 to 2012. Asterisk indicates 
a statistically significant increase from 2008 to 2012 (p < .005). 
Reproduced with permission from Dyer et al61
(A)
(B)
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severity, although presence of asthma and asthma exacerbation 
were identified as mortality risk factors.73 A 2018 meta-analysis of 
32 published studies of food-related anaphylaxis, which found that 
peanut and tree nuts were the leading triggers of fatal anaphylaxis, 
also showed that a history of asthma in young adults was an impor-
tant risk factor for fatality.77
3.5  |  Comorbidities
Comorbid conditions including allergic rhinitis, atopic dermatitis and 
asthma, as well as other food allergies, are very common in patients 
with PA (Table 3)4,6; in the French MIRABEL study, only 5% of indi-
viduals had no associated allergic comorbidity.4 Comorbid tree nut 
allergy is particularly common in patients with PA, with reported 
prevalence ranging from approximately 16%–50%.7,78 In tree nut‒al-
lergic patients, reported concomitant PA ranges from 20% to 68%.79 
Increased number of food allergies tends to increase the burden due 
to the added requirements of vigilance and dietary restriction.80
4  |  THE BURDEN OF PE ANUT ALLERGY 
ON THE INDIVIDUAL
4.1  |  Dietary restrictions
The primary strategies for allergen avoidance in patients with PA 
and their families are diet modification and restrictive eating hab-
its, which has a substantial impact on quality of life (QoL).18 These 
strategies also carry the risks of nutritional deficiency and compro-
mised growth in young children, particularly if parents exclude a 
wider-than-necessary range of foods without expert nutritional con-
sultation.81–83 Individuals with PA often avoid tree nuts, in part be-
cause of concern over cross-reactivity or contamination.49 However, 
studies that investigated rates of coexistence of nut allergies have 
shown that performance of SPT or basophil activation tests or OFCs 
for various nuts in children with one or more PA or other nut aller-
gies could result in relief of dietary restrictions.84,85 In the PRONUTS 
study, the use of OFC to confirm tolerance of specific nuts in chil-
dren with ≥1 nut allergy led to a median of 9 nuts being introduced 
into the diets of study participants.85
4.1.1  |  Reading food labels: precautionary 
allergen labels
Mandatory requirements for allergen labelling in food items are well 
established in developed and developing countries and are typically 
clear and useful.86 However, precautionary allergen labelling is not 
legally required in most countries, is mostly unregulated and may 
be confusing for consumers.86 In a US study of prepackaged food, 
labelling for just under half of products included had a ‘may contain’ 
type of advisory label.87 A 2017 study from France found that of 
more than 17,000 food products, 1% included peanut in the ingredi-
ent list, yet 13% of products contained a precautionary statement 
listing peanut.88 In addition, an investigation by the Food Standards 
Agency in the UK found that approximately 20% of food samples 
in England contained an undeclared allergen, the majority of which 
TA B L E  3  Selected studies reporting comorbidities in children with peanut allergy
Comorbidity
Studies, % participants with comorbidity
Neumann-
Sunshine et al 
(2012)49 (n = 782)
Deschildre et al 
(2015)4 (n = 785)
Dyer et al 
(2015)7 (n = 754)
Leickly et al 
(2018)6 (n = 1070)
Johnston et al 
(2019)153 (n = 496)
Fleisher et al 
(2019)31 (n = 356)
Atopic dermatitis 70.8 66 NR 65 62 61.2
Allergic rhinitis 57.3 49 NR NR 72 55.9
Asthma 55.8 58 NR 41 53 47.5
EoE 3.1 NR NR NR NR NR
Other food allergies
Any 93.1a  62 NR 68.7 66 NR
Tree nuts 87.6 NR 15.6 NR NR NR
Milk 35.7 NR 10.8 19.9 NR NR
Soy 13.2 NR 3.6 NR NR NR
Egg 39.5 NR 8.5 40.2 NR NR
Wheat 11.0 NR 3.6 NR NR NR
Sesame 23.3 NR 3.0 NR NR NR
Other legume 4.1 NR NR NR NR NR
Other 40.8 NR NR NR NR NR
Abbreviations: EoE, eosinophilic oesophagitis; NR, not reported.
aAvoiding other foods whether a food allergy had been diagnosed or not. 
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were peanuts.89 In a longitudinal, prospective cohort study in the 
Netherlands, among 157 patients with food allergy, including 71% 
with PA, 73 reported 151 accidental reactions to an allergen, of 
which 118 (78%) could be attributed to a specific product.90 Of the 
51 food products that fulfilled criteria for further analysis, 19 (37%) 
contained 1–4 allergens (including peanut) that were unidentified in 
the product labelling.
Several studies have shown that using unregulated language 
in advisory statements on food labels may create uncertainty for 
consumers. A US-based study showed that only 4.5% of products 
with advisory labelling specific to peanuts tested positive for pea-
nut residue, further unnecessarily restricting diet choices.91 In ad-
dition, shoppers increasingly ignore labels,92 with up to 40% of US 
and Canadian consumers who either have a food allergy or care for a 
food-allergic child stating they had purchased food despite the prod-
uct's precautionary labelling, in one study (Table S2).93 The French 
MIRABEL study found that accidental exposure peanut doses elicit-
ing reactions were <100 mg in 44.3% of study participants with PA; 
however, such data have not been incorporated into clear and uni-
versal labelling regulations.4 The quantity of accidentally ingested 
peanut leading to symptoms in patients with PA appears to vary 
widely and is not well studied.
The lack of consensus for standard labelling impairs the ability 
of healthcare professionals to provide an effective management 
approach and may indirectly impact emotional adjustment, social 
interactions and coping strategies,94–97 causing increased anxiety 
and impaired QoL.98 Recent recommendations from The National 
Academies of Sciences, Engineering and Medicine (NASEM) high-
lighted the importance of evaluating and improving food labels with 
allergen information.99
4.1.2  |  Eating at restaurants
Eating food made outside of the home can also impact patients with 
PA, as peanut is a common ingredient in many dishes. The 2017 
NASEM consensus report recommended that patients and their par-
ents be guided to always inform restaurants (eg servers, managers, 
cooks) of food allergies to minimize risk of exposure.99 The European 
Commission of the European Union also issued legislation effec-
tive December 2014 including ‘mandatory allergen information for 
non-prepacked food, including in restaurants and cafes’.100 In 2019, 
the European Federation of Allergy and Airways Diseases Patients’ 
Associations released a report calling for additional improvements 
to food labelling and safety measures at restaurants.101
A survey of children with peanut and tree nut allergy who experi-
enced a reaction due to exposure at a restaurant (dine-in or takeout) 
found that most reactions (81%) were due to accidental exposure 
in children who had already been diagnosed; yet allergic individu-
als or their parents alerted restaurant personnel about the allergy 
less than half (45%) of the time.102 Surveys of restaurant workers 
in the US, UK, Turkey and Malaysia have demonstrated a poor un-
derstanding of food allergies and appropriate measures for avoiding 
allergens.103–109 A UK interview study found that individuals with 
food allergy strongly preferred written information to be provided in 
restaurants.110 Respondents further reported they practised avoid-
ance as a last resort if uncertain.
4.2  |  Restrictions on daily activities
The risk of accidental exposure posed by PA extensively impacts 
daily activities, which may include playdates at friends’ homes, at-
tendance at daycare or afterschool care, parties and sports events, 
and camp and sleepovers.111
4.2.1  |  Travel
Individuals with PA must take extra precautions in trip planning. A 
survey of this population in the UK highlighted several such consid-
erations, including ability to understand the language at the destina-
tion, perceived experience on airlines, accessibility to medical care, 
familiarity with the destination and avoiding unfamiliar cuisines.112
An international study of 3273 respondents with peanut and/or 
tree nut allergy from 11 countries found that 349 reactions to pea-
nuts or tree nuts occurred aboard flights, with 13.3% of respondents 
receiving adrenaline for their reactions.113 In addition, flight crews 
were notified of the reactions in only 50.1% of cases. However, 69% 
F I G U R E  4  Settings of first and subsequent reactions among 
5149 registrants in a peanut and tree nut allergy registry, of whom 
89% were children (aged <18 years), 68% had isolated peanut 
allergy, and 23% had both peanut and tree nut allergy. Accidental 
exposures to peanut subsequent to the first reaction occurred 
increasingly at school settings. ‘Other’ locations include workplace, 
stores, malls, sporting event sites, transportation vehicles and 
houses of worship. Reproduced with permission from Sicherer 
et al48
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of respondents made preflight accommodation requests (55% of re-
actors vs. 71.6% of nonreactors; p < .001).
4.2.2  |  School
European meta-analysis data indicate that food allergy affects 
4%–7% of primary school children, and approximately 8%–20% of 
paediatric food-related accidental reactions and anaphylaxis reac-
tions may occur at school.114 Peanut was the most common trigger 
among 105 cases of food-induced anaphylaxis (25% of cases) at 
school documented in a French national allergy database115 and 
was the second most common food trigger of anaphylaxis (16%), 
after tree nuts (23%), occurring in school settings in one German 
study (n = 87 anaphylaxis cases).115,116 A US study of all food-al-
lergic reactions due to accidental exposure at school found that 
25%–29% of reactions were attributed to peanut.117 In a survey 
study of parents of children with PA or tree nut allergy in the US 
Peanut and Tree Nut Registry (n = 4586), 16% of respondents re-
ported a reaction at daycare, preschool or elementary school.118 
Of the 124 total reactions (115 to peanut), 65 (52.4%) were severe 
and 71 (57.3%) were treated with adrenaline. A further study in 
this registry population (n = 5149) also found that as children got 
older, school was increasingly the setting for accidental exposures 
subsequent to the child's first reaction (Figure 4).48
Multiple studies in various countries have examined potential strat-
egies for schools to address the risks of food allergies, such as becoming 
‘peanut-free’ and making adrenaline available to school staff, with some 
controversy.115,116,119–127 A survey of school nurses in Massachusetts 
found that 10.3% of schools do not permit peanuts to be sent in from 
home, 91.1% had peanut-free tables, and 65.6% had peanut-free class-
rooms.128 However, a study investigating the impact of peanut-free 
schools on the PA-related burden and QoL of parents demonstrated no 
difference compared with schools that are not peanut-free.129
F I G U R E  5  Bullying: respondents who reported having been bullied because of their/their child's food allergy (n = 85) from a survey study 
in 353 individuals with food allergy, including 287 (81.3%) with peanut allergy. Panel A describes the perpetrators of the bullying. Panel B 
describes the types of physical bullying. Panel C shows the reported emotional effects of bullying. For each parameter, respondents could 
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4.3  |  Emotional impact
Living with food allergy can lead to fear and anxiety not only regard-
ing the risk of exposure and reaction to the allergen,111 but also fear 
of using a prescribed AAI, possibly related to uncertainty of how and 
when to use it and past or anticipated traumatic experiences of se-
vere reactions.19,130–132 In those with PA, factors such as comorbid 
illnesses and experience of PA may also play a role. The MIRABEL 
study in 785 children with PA found that higher anxiety scores 
(n = 401 evaluated for anxiety) were observed in patients with atopic 
dermatitis (p = .003), both atopic dermatitis and asthma (p = .032), and 
those who had received strict avoidance advice (p < .001).4 Dietary 
avoidance itself may also be a source of anxiety and stress.18,133
Bullying, teasing and taunting because of food allergy have been 
reported among children with food allergy in studies at rates ranging 
from 16% to 71%, causing substantial adverse emotional impact.134 
Data specifically on bullying in children and adolescents with PA are 
scant. One survey study of children and adults with food allergy in-
cluded 287 individuals with PA.135 In this study, 24.1% reported having 
been bullied, harassed or teased because of their food allergy by a va-
riety of perpetrators (Figure 5A). After excluding children younger than 
5 years, the rate increased to 35.2%. The great majority of those bul-
lied, teased or harassed (85.9%) reported physical acts of bullying such 
as having the allergen waved in their face (Figure 5B); nonphysical acts 
included verbal teasing and exclusion. The most common reported 
emotional effects of the bullying were sadness and depression, em-
barrassment and humiliation, and nervousness and anxiety (Figure 5C).
4.4  |  Impact on health-related quality of life/
quality of life
Multiple studies have demonstrated adverse impacts of food allergy 
on HRQoL and QoL in people with food allergies and their parents/
caregivers.132,136,137 Several studies also evaluated the effects of PA 
specifically on HRQoL, which is of particular interest since PA is as-
sociated with relatively high rates of prevalence, accidental expo-
sures, severe reactions and anaphylaxis, as discussed above.17–19,80
F I G U R E  6  Scores on specific questionnaire items in study comparing quality of life in children with peanut allergy (blue bars; n = 20) and 
diabetes mellitus (orange bars; n = 20). A, Fear of eating peanuts/having a hypoglycaemic event; B, Chance of having a bad reaction and 
getting very sick; C, I have to be very careful about what I eat; D, I must take care when eating in a restaurant17
(A) (B)
(C) (D)
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A recent study surveyed parents of children aged <13 years with 
PA (n = 717), sesame allergy (n = 34) or seafood allergy (n = 42) using 
the Food Allergy Quality of Life Questionnaire—Parent Form.80 
Mean QoL scores (higher scores = worse QoL) were similar for PA 
(2.53) and sesame allergy (2.56), but scores were significantly worse 
for PA (but not sesame allergy) compared with seafood allergy (1.97; 
0.55 difference, 95% CI: 0.13–0.98). An older study compared QoL of 
children with PA (n = 20; mean age 9.0 years) and diabetes mellitus 
(n = 20; mean age 10.4 years) using a QoL questionnaire developed for 
the study (which has since been validated)138 and an adapted Vespid 
Allergy Quality of Life questionnaire.17 In this study, mean scores were 
significantly higher (worse) in children with PA vs those with diabetes 
in both questionnaires (54.9 for PA vs 46.4 for diabetes; p = .004 [novel 
questionnaire] and 54.3 for PA vs 34.5 for diabetes; p ≤ .001 [adapted 
Vespid questionnaire]) (Figure 6). The children with PA were also re-
ported to experience significant anxiety in a wide range of settings.17
A study in 46 families that included a child with clinically con-
firmed PA, and which used validated QoL and anxiety and stress 
scales, reported significantly worse scores for physical HRQoL 
(p < .05), QoL within school (p < .01), general QoL (p < .05) and greater 
separation anxiety (p < .05) in children with PA than in their siblings 
without PA.18 Mothers had significantly worse scores for psycholog-
ical and physical health, and higher levels of anxiety and stress than 
fathers. However, another study, which examined HRQoL, anxiety 
and stress levels in 51 families including a child with PA, found that 
many measures did not significantly differ from population norms.19 
This study also found that parental stress and child anxiety levels 
varied with clinical history and that both parent and child percep-
tions of their own HRQoL were affected by each other's anxiety and 
stress levels. Children's QoL was also adversely affected by length 
of time since diagnosis and the experience of having to self-inject or 
receive an AAI injection.
Depending on the management strategies employed by children 
with PA and their families, the impact of PA on QoL is variable.139 
Further, management of PA by paediatric allergy specialists has been 
shown to slightly improve QoL,140 demonstrating a crucial role for 
allergists and immunologists in helping allergic children and their 
families manage this burden.
TA B L E  4  The state of knowledge on the burden of peanut allergy and future needs: an overall assessment
Area of 
assessment Current knowledge and needs
What is known PA affects 1%–2% of the general population, and appears to be increasing in prevalence and incidence, in Western nations
PA is typically lifelong and is associated with high rates of severe reactions and anaphylaxis due to accidental exposures, 
compared with other food allergies
Peanut is among the most frequent allergens implicated in documented cases of fatal food-related anaphylactic reactions
PA is associated with high rates of healthcare utilization and costs
The risks of PA impose restrictions in multiple activities of daily living for patients, parents and caregivers, including food 
shopping, dining out, socializing, schooling and travel
Management of PA risks in consumer food labelling, and accommodations at schools, restaurants, and travel are inconsistent 
and often inadequate
Bullying of children with PA is common, causing emotional impacts including sadness, humiliation and social isolation
QOL is significantly reduced for patients with PA, parents and caregivers, possibly more so than in other chronic diseases
What is likely The incidence of PA may increase in regions other than Western/advanced nations as they adopt Western styles of diet and 
paediatric nutrition management
Costs of future PA treatments may meet with acceptance if they approximate the current costs of AAIs
Recent guidelines for prevention of PA in infants may stabilize or decrease PA prevalence and incidence
What is needed Improved and more consistent methodology for study of PA epidemiology
More and better data on PA epidemiology from geographic regions other than Western/advanced countries
More and better data on the healthcare utilization and costs of PA from regions/countries other than the US and UK
Standardized, clear, and evidence-based food labelling for peanut content
Increased knowledge/studies on the amount of peanut in foods that will cause reactions and the circumstances of/risk 
factors for accidental reactions (eg where they occur)
Improved and more consistent standards for accommodations for individuals with PA at public establishments such as 
restaurants, schools and travel conveyances
More accurate QOL instruments adapted specifically for PA including those that may measure the impacts of treatment of 
PA on QOL
Treatments that reduce the risk of severe reactions due to accidental exposure to peanut and may alleviate the burden of PA
Further studies to assess peanut OIT efficacy and safety, establish validated protocols for optimal dosing and duration of 
therapy and assess impact on QOL and cost-effectiveness.
Abbreviations: OIT, oral immunotherapy; PA, peanut allergy; QOL, quality of life.
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5  |  CONCLUSIONS
The incidence and prevalence of PA appear to be increasing, 
and rates of accidental exposure in patients with PA are high, 
despite extensive efforts at avoidance. Patients with PA and 
their families experience significant psychosocial and economic 
ramifications from PA allergy, resulting in a negative impact on 
HRQoL/QoL. Multiple new approaches and initiatives towards 
better understanding of PA risks and improved PA management 
are clearly needed (Table 4). Introduction of peanut to children 
at a young age may reduce the risk of developing PA,23 and inter-
national guidelines for the use of this approach have been pro-
vided.24–26 However, such prevention practices do not address 
those with PA or who develop PA despite this new guidance. 
While the approval of the first oral immunotherapy product for 
PA27 is a major advance, the ultimate benefit of this therapy 
and other new treatments will likely depend on multiple fac-
tors including baseline disease severity, the cost-effectiveness 
of immunotherapies vs adrenaline, effects of immunotherapy 
on QoL, and the ability to induce sustained unresponsiveness.15 
Continued research into the burden of PA remains essential to 
provide perspectives for current and future developments in 
PA management.
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